Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
electroCore, Inc.
Report date March 28, 2019 · Filed April 01, 2019
Section 16 reporting ended · disclosed 2019-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,612 |
Reported balance
After 2019-03-28 transaction · row 1
1 source rowRow 1 · 2019-03-28 · Grant · Acquired 8,976 · Balance 163,612 F1: On March 28, 2019, the Reporting Person was granted 8,976 shares of restricted stock and options to purchase 47,000 shares of Common Stock of the Issuer. 50% of the restricted stock and the options vest on December 31, 2019, and the remainder vests in equal annual installments over the succeeding two-year period |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 | Direct | 47,000 |
Reported balance
After 2019-03-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-28 · Grant · Acquired 47,000 · Balance 47,000 F1: On March 28, 2019, the Reporting Person was granted 8,976 shares of restricted stock and options to purchase 47,000 shares of Common Stock of the Issuer. 50% of the restricted stock and the options vest on December 31, 2019, and the remainder vests in equal annual installments over the succeeding two-year period F2: The options have an expiration date one year after the termination or expiration of the Letter Agreement, dated as of March 28, 2019, between the Reporting Person and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectVia Spouse | 6,597 |
Reported balance
Holding disclosure · report date 2019-03-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,597 |
| Common StockSEC Table I · non-derivative | Indirectvia WaveCore LLC | 12,843 |
Reported balance
Holding disclosure · report date 2019-03-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,843 |
| Common StockSEC Table I · non-derivative | Indirectvia Core Ventures II, LLC | 237,825 |
Reported balance
Holding disclosure · report date 2019-03-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 237,825 |
| Common StockSEC Table I · non-derivative | IndirectVia by Core Ventures IV, LLC | 55,542 |
Reported balance
Holding disclosure · report date 2019-03-28 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 55,542 |
Filing footnotes · ownership attribution and instrument terms
F1: On March 28, 2019, the Reporting Person was granted 8,976 shares of restricted stock and options to purchase 47,000 shares of Common Stock of the Issuer. 50% of the restricted stock and the options vest on December 31, 2019, and the remainder vests in equal annual installments over the succeeding two-year period
F2: The options have an expiration date one year after the termination or expiration of the Letter Agreement, dated as of March 28, 2019, between the Reporting Person and the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2019 Filed Apr 1, 2019 21:48 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0000899243-19-009476 · doc4.xml · derivative · entry 6 Staats Peter S. · CIK 0001737600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires not disclosed F1 · date: On March 28, 2019, the Reporting Person was granted 8,976 shares of restricted stock and options to purchase 47,000 shares of Common Stock of the Issuer. 50% of the restricted stock and the options vest on December 31, 2019, and the remainder vests in equal annual installments over the succeeding two-year period F2 · derivative.expiration_date: The options have an expiration date one year after the termination or expiration of the Letter Agreement, dated as of March 28, 2019, between the Reporting Person and the Issuer. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 21:48 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 8,976 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009476 · doc4.xml · nonDerivative · entry 1 Staats Peter S. · CIK 0001737600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,612 F1 · date: On March 28, 2019, the Reporting Person was granted 8,976 shares of restricted stock and options to purchase 47,000 shares of Common Stock of the Issuer. 50% of the restricted stock and the options vest on December 31, 2019, and the remainder vests in equal annual installments over the succeeding two-year period Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 11:10 UTC | electroCore, Inc. ECOR · Entity 6900 | PurchaseCommon Stock | 10,000 | $4.83 | $48,300.00 |
DisclosureSEC source: 0001209191-18-062861 · doc4.xml · nonDerivative · entry 1 Staats Peter S. · CIK 0001737600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,636 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.73 to $4.91 per share. The reporting person undertakes to provide to electroCore, Inc., any security holder of electroCore, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on December 13, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.